-
1
-
-
34547863123
-
Efficiency and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
-
for Stein P for the Sitagliptin 035 Study Group
-
Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H. Efficiency and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:737-745. for Stein P for the Sitagliptin 035 Study Group.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 737-745
-
-
Hermansen, K.1
Kipnes, M.2
Luo, E.3
Fanurik, D.4
Khatami, H.5
-
2
-
-
77949387699
-
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
-
Sitagliptin Study 024 Group
-
Seck T., Nauck M., Sheng D., Sunga S., Davies M.J., Stein P.P., et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010, 64:562-576. Sitagliptin Study 024 Group.
-
(2010)
Int J Clin Pract
, vol.64
, pp. 562-576
-
-
Seck, T.1
Nauck, M.2
Sheng, D.3
Sunga, S.4
Davies, M.J.5
Stein, P.P.6
-
3
-
-
79956315355
-
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
-
Reasner C., Olansky L., Seck T.L., Williams-Herman D.E., Chen M., Terranella L., et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13:644-652.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 644-652
-
-
Reasner, C.1
Olansky, L.2
Seck, T.L.3
Williams-Herman, D.E.4
Chen, M.5
Terranella, L.6
-
4
-
-
34547660561
-
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
-
for the Sitagliptin 036 Study Group
-
Goldstein B.J., Johnson J., Feinglos M.N., Williams-Herman D.E., Lunceford J.K. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987. for the Sitagliptin 036 Study Group.
-
(2007)
Diabetes Care
, vol.30
, pp. 1979-1987
-
-
Goldstein, B.J.1
Johnson, J.2
Feinglos, M.N.3
Williams-Herman, D.E.4
Lunceford, J.K.5
-
5
-
-
39749184723
-
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
-
Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24:537-550.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 537-550
-
-
Raz, I.1
Chen, Y.2
Wu, M.3
Hussain, S.4
Kaufman, K.D.5
Amatruda, J.M.6
-
6
-
-
78751562877
-
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
-
Yoon K.H., Shockey G.R., Teng R., Golm G.T., Thakkar P.R., Meehan A.G., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract 2011, 65:154-164.
-
(2011)
Int J Clin Pract
, vol.65
, pp. 154-164
-
-
Yoon, K.H.1
Shockey, G.R.2
Teng, R.3
Golm, G.T.4
Thakkar, P.R.5
Meehan, A.G.6
-
7
-
-
77957741412
-
Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men
-
Aoki K., Masuda K., Miyazaki T., Togashi Y., Terauchi Y. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 2010, 57:667-672.
-
(2010)
Endocr J
, vol.57
, pp. 667-672
-
-
Aoki, K.1
Masuda, K.2
Miyazaki, T.3
Togashi, Y.4
Terauchi, Y.5
-
8
-
-
41849099939
-
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
-
Mistry G.C., Maes A.L., Lasseter K.C., Davies M.J., Gottesdiener K.M., Wagner J.A., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008, 48:592-598.
-
(2008)
J Clin Pharmacol
, vol.48
, pp. 592-598
-
-
Mistry, G.C.1
Maes, A.L.2
Lasseter, K.C.3
Davies, M.J.4
Gottesdiener, K.M.5
Wagner, J.A.6
-
9
-
-
79956326006
-
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
-
Esposito K., Cozzolino D., Bellastella G., Maiorino M.I., Chiodini P., Ceriello A., et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011, 13:594-603.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 594-603
-
-
Esposito, K.1
Cozzolino, D.2
Bellastella, G.3
Maiorino, M.I.4
Chiodini, P.5
Ceriello, A.6
-
10
-
-
79952310049
-
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
-
Nauck M.A., Vardarli I., Deacon C.F., Holst J.J., Meier J.J. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia 2011, 54:10-18.
-
(2011)
Diabetologia
, vol.54
, pp. 10-18
-
-
Nauck, M.A.1
Vardarli, I.2
Deacon, C.F.3
Holst, J.J.4
Meier, J.J.5
|